A SINGLE BLIND, MULTI-CENTE, RANDOMIZED MULTINATIONAL PHASE III STUDY TO COMPARE THE EFFICACY AND TOLERABILITY OF ANAGRELIDE VS HYDROXYUREA IN PATIENTS WITH ESSENTIAL THROMBOCYTHAEMIA

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-000874-30-IT

Enrollment

220

Registered

2006-02-02

Start date

2004-07-12

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

essntial thrombocythaemia MedDRA version: 6.1 Level: PT Classification code 10043549

Interventions

Trade Name: THROMBOREDUCTIN Pharmaceutical Form: Capsule, hard Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .5- Pharmaceutical Form: Capsule, hard INN or Propos

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026